Life sciences company Ananda Developments PLC (AQSE: ANA) announced on Wednesday that it has contracted Southern Star Research Pty Ltd, an Australian Contract Research Organisation, to conduct a Phase 1 clinical trial for its lead investigative asset, MRX1.
This study will assess the pharmacokinetic (PK) profile, tolerability and safety of MRX1 in 20 healthy volunteers.
To be conducted in Australia, the trial will generate crucial data for future regulatory applications with agencies such as the MHRA and FDA.
The decision to conduct the study in Australia provides financial benefits, including a 43.5% R&D tax incentive.
This trial is a key step in advancing MRX1, an oral drug candidate aimed at treating complex inflammatory pain conditions, with Phase 2 trials planned for chemotherapy-induced peripheral neuropathy and endometriosis.
Johnson & Johnson seeks approval for DARZALEX FASPRO in smoldering multiple myeloma
FDA Panel supports IceCure's ProSense Cryoablation for early-stage breast cancer
Dizal submits NDA to US FDA for sunvozertinib in treating NSCLC with EGFR exon 20 mutations
Naitive Technologies enters strategic agreement with Parvizi Surgical Innovation
Akura Medical's application for trial of Katana Thrombectomy System receives US FDA approval
FDA accepts Ionis Pharmaceuticals' donidalorsen New Drug Application
Kazia Therapeutics secures FDA meeting to explore paxalisib pathways for glioblastoma
Boston Scientific to acquire Cortex Inc in strategic expansion of electrophysiology portfolio
Formosa Pharmaceuticals signs licensing agreement with DÁVI Farmaceutica
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation